Glyko launches FACE lysosomal disease screening test.
This article was originally published in The Gray Sheet
Executive Summary
GLYKO BIOMEDICAL BEGINS SALES OF FACE LYSOSOMAL DISEASE SCREEN following 510(k) clearance of the product on Nov. 3. The company says that the FACE (Fluorophore-Assisted Carbohydrate Electrophoresis) Urinary Carbohydrate Analysis Kit is the first FDA-cleared product for identification of "abnormal" carbohydrates associated with lysosomal diseases. The test can screen children for more than 25 lysosomal diseases, which stem from hereditary defects in the lysosomal enzymes that break down and recycle carbohydrates. The disorders, resulting from the accumulation in the body of incompletely degraded sugar chains, include Tay-Sachs, Gaucher's, Hurler and Hunter MPS diseases.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.